A Phase III Long-Term Extension Trial With Optional Additional Doses of CYB003 to Assess the Safety and Long-term Efficacy in Participants With Major Depressive Disorder (EXTEND)
This is a long- term extension of the double-blind trials APPROACH (CYB003-002) and EMBRACE (CYB003-003). Its aim is to examine the safety and long-term efficacy of CYB003 in participants with MDD.
- Status
- enrolling by invitation
- Phase
- Phase 3
- Institution
- Cybin IRL Limited
- Principal investigator
- Clinical Development
- Start date
- 2025-07-18
- End date
- 2028-03-15
- Registry ID
- NCT06605105
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.